Key Points
- Pharvaris director Viviane Monges sold 9,667 shares on May 21 at an average price of $30.29, totaling about $292,813. After the sale, she held 5,500 shares, a 63.74% reduction in ownership.
- PHVS stock was slightly higher, opening at $29.88 and rising 0.7% as the company’s market cap stood near $1.95 billion. The shares have traded between a 52-week low of $15.46 and a high of $33.33.
- Pharvaris beat quarterly earnings expectations, reporting EPS of -$0.70 versus the consensus estimate of -$0.82. Analyst sentiment remains generally positive, with a consensus rating of Moderate Buy and an average price target of $49.18.
Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) insider Anna Nijdam sold 1,829 shares of the business's stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $30.60, for a total transaction of $55,967.40. Following the sale, the insider owned 48,945 shares of the company's stock, valued at $1,497,717. This trade represents a 3.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Anna Nijdam also recently made the following trade(s):
- On Friday, May 22nd, Anna Nijdam sold 5,501 shares of Pharvaris stock. The shares were sold at an average price of $30.74, for a total transaction of $169,100.74.
Pharvaris Trading Up 0.7%
Shares of PHVS stock opened at $29.88 on Wednesday. The firm has a market capitalization of $1.95 billion, a PE ratio of -9.40 and a beta of -2.34. The firm has a fifty day simple moving average of $28.61 and a two-hundred day simple moving average of $26.96. Pharvaris N.V. has a 12 month low of $15.46 and a 12 month high of $33.33.
Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, beating analysts' consensus estimates of ($0.82) by $0.12. On average, equities analysts predict that Pharvaris N.V. will post -3.25 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of brokerages have commented on PHVS. Citizens Jmp decreased their price target on shares of Pharvaris from $75.00 to $74.00 and set a "market outperform" rating for the company in a research note on Wednesday, May 13th. Citigroup restated a "buy" rating on shares of Pharvaris in a research note on Wednesday, April 15th. HC Wainwright reaffirmed a "buy" rating and set a $60.00 price objective on shares of Pharvaris in a report on Tuesday, March 3rd. Wall Street Zen raised shares of Pharvaris from a "strong sell" rating to a "sell" rating in a report on Saturday, May 16th. Finally, Royal Bank Of Canada cut their price objective on shares of Pharvaris from $52.00 to $51.00 and set an "outperform" rating on the stock in a report on Monday, April 6th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Pharvaris has an average rating of "Moderate Buy" and a consensus target price of $49.18.
Check Out Our Latest Stock Analysis on Pharvaris
Hedge Funds Weigh In On Pharvaris
Hedge funds have recently bought and sold shares of the company. GF Fund Management CO. LTD. purchased a new position in Pharvaris during the 4th quarter worth $35,000. Barclays PLC purchased a new position in Pharvaris during the 4th quarter worth $77,000. China Universal Asset Management Co. Ltd. purchased a new position in Pharvaris during the 3rd quarter worth $75,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Pharvaris in the 4th quarter worth about $86,000. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company's stock worth $59,000 after buying an additional 783 shares during the last quarter.
About Pharvaris
(
Get Free Report)
Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.
The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
